Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya(R) for the Treatment of Posttraumatic Stress Disorder

Source :: GlobeNewswire. April 22, 2019
Publication Year :: 2019
Abstract: NEW YORK, April 22, Apr 22, 2019 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to [...]

Subjects :: United States. Food and Drug Administration
Biological products
Cyclobenzaprine
Post-traumatic stress disorder
Backup software
Pain management
Biological weapons
Pharmaceutical industry
Bioterrorism
Banking, finance and accounting industries
Business

Tools